TY  - JOUR
TI  - Use of intranasal esketamine in the treatment of treatment-resistant depression: A case report
AU  - Jerotić, Stefan
AU  - Poleksić, Joko
AU  - Ivković, Maja
AU  - Latas, Milan
T2  - Serbian Journal of the Medical Chamber
AB  - Introduction: Treatment-resistant depression (TRD) refers to a depressive episode that has not responded to treatment with two antidepressants. Pharmacological strategies for treating TRD involve a complex process, which includes several options for the use of different psychopharmaceuticals, fundamentally consisting of: (1) substituting/optimizing the dose of antidepressants, or (2) augmenting antidepressant therapy. Within the augmentation strategy, NMDA antagonists, including intranasal esketamine, play a significant role. Current research suggests that the application of intranasal esketamine as an augmentation agent is an effective pharmacological strategy in the treatment of TRD. Case report: In this paper, we present the successful application of intranasal esketamine in co-administration with a serotonin/norepinephrine reuptake inhibitor (SNRI antidepressant) in a patient with TRD. Conclusion: Further research is necessary to better understand the mechanisms of action, dosing modalities, as well as the long-term outcomes and safety profile of this approach.
DA  - 2024///
PY  - 2024
DO  - 10.5937/smclk5-51004
VL  - 5
IS  - 2
SP  - 239
EP  - 247
SN  - 2737-9752
UR  - https://www.smj.rs/en/volume-5-no-2/use-of-intranasal-esketamine-in-the-treatment-of-treatment-resistant-depression-a-case-report
ER  -